Your fact-checks will appear here
The text mentions that pharmacokinetic modeling and trials for malaria transmission have explored regimens to extend time above mosquitocidal thresholds.
The balance of high-quality evidence does not support ivermectin as a proven treatment for : and rigorous reviews have generally found no clear clinical benefit, and major health bodies recommend agai...
Ivermectin is FDA‑approved for a small set of parasitic indications in humans—oral tablets for certain internal worms and topical formulations for external parasites and some skin conditions—but it is...
Ivermectin is FDA‑approved in humans for specific antiparasitic indications: oral tablets (Stromectol) for intestinal strongyloidiasis and onchocerciasis, and topical formulations for certain skin con...
Several large, high-quality randomized controlled trials have tested ivermectin as a treatment for COVID‑19, and the consensus from regulators and later trials is that these trials did not show meanin...
Ivermectin can cause common, usually mild adverse effects such as headache, nausea, dizziness, diarrhea, and skin rash when given at approved human doses . Serious but rare harms include neurological ...
Ivermectin formulations and doses differ by species and by indication; human-approved products are single-dose oral tablets or topical creams with standard weight‑based dosing (generally 150–200 µg/kg...
Randomized trials that directly tested ivermectin as post‑exposure prophylaxis (PEP) for SARS‑CoV‑2 are few, heterogeneous in design, and report mixed results — one reported a large protective effect ...
A large and disparate body of clinical research tested ivermectin for COVID‑19 using regimens ranging from single low antiparasitic doses (≈150–200 μg/kg) to multi‑day high‑dose courses (including stu...
’s reputation as a neurotoxin rests largely on reports of overdose, rare encephalopathy in specific parasitic co‑infections, and animal data showing CNS effects at high concentrations; conversely, a s...
Raising ivermectin concentrations in humans can be approached by higher or more frequent oral dosing, formulation and route changes (controlled‑release, parenteral or inhaled delivery), and pharmacoki...
Clinical trials and protocols demonstrate that ivermectin has been given to humans at doses above 400 μg/kg—ranging from multiple trials testing 600 μg/kg and planned 1,200 μg/kg regimens to a formal ...
Randomized trials and dozens of meta-analyses have examined ivermectin for COVID‑19, producing contradictory signals: early meta‑analyses reported large mortality and recovery benefits while later, la...
Regulators including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the World Health Organization (WHO) do not recommend ivermectin for prevention or treatment of...
Randomized trials of ivermectin for COVID-19 and other indications report adverse events spanning neurological, gastrointestinal, dermatologic, ocular, and systemic (including multiorgan failure) cate...
Randomized and observational studies have tested five‑day ivermectin regimens almost exclusively in the context of COVID‑19, producing a patchwork of contradictory results: small trials from Banglades...
Clinical pharmacology studies disagree on the size of the food effect for oral ivermectin but converge on the direction: fatty (high‑fat) meals increase systemic exposure. Depending on the study popul...
Cumulative exposure to ivermectin raises toxicity risk primarily by increasing systemic drug levels, exposing vulnerable life stages, and enabling subclinical damage that may emerge over time — patter...
Clinical studies that describe "chronic" ivermectin use do not have a single standardized threshold; in the human trials reviewed, most chronic-use patterns meant multi-day or repeated dosing (for exa...
Completed randomized trials that tested ivermectin explicitly as prophylaxis against SARS‑CoV‑2 infection are few, small, and heterogeneous in design; the clearest randomized pre‑exposure prophylaxis ...
Ivermectin is an antiparasitic medication approved for specific human uses including oral treatment of intestinal strongyloidiasis and onchocerciasis, and topical formulations for certain dermatologic...